Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

99 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Epidermal growth factor receptor: a promising target in solid tumours.
Laskin JJ, Sandler AB. Laskin JJ, et al. Among authors: sandler ab. Cancer Treat Rev. 2004 Feb;30(1):1-17. doi: 10.1016/j.ctrv.2003.10.002. Cancer Treat Rev. 2004. PMID: 14766123 Review.
A phase II trial of paclitaxel in refractory germ cell tumors.
Sandler AB, Cristou A, Fox S, Williams SD, Nichols CR, Turns M, Roth BJ. Sandler AB, et al. Cancer. 1998 Apr 1;82(7):1381-6. doi: 10.1002/(sici)1097-0142(19980401)82:7<1381::aid-cncr23>;2-1. Cancer. 1998. PMID: 9529032 Clinical Trial.
The influence of gemcitabine and cisplatin schedule on response and survival in advanced non-small cell lung cancer.
Shepherd FA, Abratt R, Crino L, Green M, Sandler A, Steward W, Iglesias J, Anglin G. Shepherd FA, et al. Lung Cancer. 2000 Nov;30(2):117-25. doi: 10.1016/s0169-5002(00)00135-5. Lung Cancer. 2000. PMID: 11086205
Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: a Phase II trial in patients with metastatic nonsmall cell lung carcinoma.
Sweeney CJ, Zhu J, Sandler AB, Schiller J, Belani CP, Langer C, Krook J, Harrington D, Johnson DH. Sweeney CJ, et al. Among authors: sandler ab. Cancer. 2001 Nov 15;92(10):2639-47. doi: 10.1002/1097-0142(20011115)92:10<2639::aid-cncr1617>;2-8. Cancer. 2001. PMID: 11745199 Clinical Trial.
Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer.
Miller VA, Johnson DH, Krug LM, Pizzo B, Tyson L, Perez W, Krozely P, Sandler A, Carbone D, Heelan RT, Kris MG, Smith R, Ochs J. Miller VA, et al. J Clin Oncol. 2003 Jun 1;21(11):2094-100. doi: 10.1200/JCO.2003.12.008. J Clin Oncol. 2003. PMID: 12775734 Clinical Trial.
The importance of the eicosanoid pathway in lung cancer.
Laskin JJ, Sandler AB. Laskin JJ, et al. Among authors: sandler ab. Lung Cancer. 2003 Aug;41 Suppl 1:S73-9. doi: 10.1016/s0169-5002(03)00145-4. Lung Cancer. 2003. PMID: 12867065 Review.
Ongoing and future trials of biologic therapies in lung cancer.
Bunn PA Jr, Shepherd FA, Sandler A, Le Chevalier T, Belani CP, Kosmidis PA, Scagliotti GV, Giaccone G. Bunn PA Jr, et al. Lung Cancer. 2003 Aug;41 Suppl 1:S175-86. doi: 10.1016/s0169-5002(03)00161-2. Lung Cancer. 2003. PMID: 12867076 Review.
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.
Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, Kay AC. Kris MG, et al. JAMA. 2003 Oct 22;290(16):2149-58. doi: 10.1001/jama.290.16.2149. JAMA. 2003. PMID: 14570950 Clinical Trial.
Molecular targeted agents in non-small-cell lung cancer.
Sandler AB. Sandler AB. Clin Lung Cancer. 2003 Sep;5 Suppl 1:S22-8. Clin Lung Cancer. 2003. PMID: 14641991 Review.
Non-small cell lung cancer and antiangiogenic therapy: what can be expected of bevacizumab?
Herbst RS, Sandler AB. Herbst RS, et al. Among authors: sandler ab. Oncologist. 2004;9 Suppl 1:19-26. doi: 10.1634/theoncologist.9-suppl_1-19. Oncologist. 2004. PMID: 15178812 Review.
99 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page